Abstract：Objective: To analyze the clinical characteristics of narcolepsy. Methods: The clinical data of 56 narcoleptic children were analyzed. Video-EEG monitoring and multiple sleep latency tests were performed in all patients. Results: Excessive daytime sleepiness was manifested in all the patients, with disrupted nocturnal sleep. Cataplexy appeared in 38cases, and hypnagogic hallucination in 4, hypnopompic hallucination in 2, and sleep paralysis in 2, respectively.EEG and VEEG of all patients were normal. The multiple sleep latency test demonstrated a short sleep la-tency (<5 minutes) and two or more sleep onset REM periods(SOREMPs) in all patients. Four patients were misdiag-nosed with myasthenia gravis. Six children were misdiagnosed with epilepsy. Two patients were misdiagnosed with schizo-phrenia. Twenty-eight mild patients were followed up at the neurological out-patient department. Two cases of sleepiness, cata-plexy and sleep hallucination was given just behavior guidance because the parents refused to receive drug treatment. Twenty six children with severe sleepiness was treated with methylphenidate along with behavior guidance. Conclusion: Narcolepsy is likely to be misdiagnosed because of its mildsymptoms at onset and atypical clinical manifestations. Misdiagnosis can be reduced by means of VEEG and MSLT.
[1] 史亮,马铁,刘永红.发作性睡病的临床研究进展[J].临床神经病学杂志,2015,28(5):394~396. [2] 王宗文,吴惠涓,赵忠新.发作性睡病的临床研究进展[J].武警医学,2016,27(6):621~625. [3] 邹慧莉,陈国艳,杨婷,等.发作性睡病误诊1例报道[J].中华实用诊断与治疗杂志,2012,26(3):308~309. [4] 王海军,高国财,郑宏.发作性睡病误诊回顾性分析[J].中国实用神经疾病杂志,2014(7):63~65. [5] American Academy of Sleep Medicine.Internationalclassification of sleep disorders(ICSD-2)[M].2nd ed.Chicago,Illinois: Am Acad Sleep Med,2005. [6] Tomi S, Outi V, Ilkka J, et al. Narcolepsy as an autoimmune disease[J].Duodecim|laaketieteellinenaikakauskirja, 2015, 131(12):1153~1160. [7] Hale L, Guan S, Emanuele E. Epidemiology of narcolepsy[M].Narcolepsy. Springer International Publishing, 2016.7~12. [8] Taheri S. The Genetics of Narcolepsy[M].Narcolepsy. Springer International Publishing, 2016.459~483. [9] Ollila H M, Ravel J M, Han F, et al. HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy[J].American Journal of Human Genetics, 2015, 96(1):136~146. [10] Liblau R S, Vassalli A, Seifinejad A, et al. Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy[J].Lancet Neurology, 2015, 14(3):318. [11] Bourgin P, Zeitzer J M, Mignot E. Hypocretin Deficiency in Human Narcolepsy[M].The Orexin/Hypocretin System. Humana Press, 2006.269~286. [12] Chemelli R M, Willie J T, Sinton C M, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation[J].Cell, 1999, 98(4):437. [13] Mignot E. Genetic and familial aspects of narcolepsy[J].Neurology, 1998, 50(2 Suppl 1):S16. [14] Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy[J].Sborni kLe karsky, 2000, 355(9197):39. [15] Allen R P. Article reviewed: Hypocretin (orexin) deficiency in human narcolepsy[J].Sleep Medicine, 2000, 1(2):147~148.
2017, Vol. 23 
冀公网安备13080202000677号